TO THE EDITOR-Wilson et al [1] demonstrated that, in human immunodeficiency virus (HIV)-infected subjects, levels of inflammatory biomarkers known to be associated with increased clinical risk (interleukin 6, D-dimer, high sensitive reactive-C protein, soluble CD14, and soluble CD163) are more closely related to markers of monocyte activation and migration than to markers of T-cell activation. These data suggest that monocytes may play a prominent role in chronic and serious non-AIDS events, such as premature cardiovascular disease and cancer. Meanwhile, several large cohort studies have demonstrated that HIVinfected subjects who do not undergo full CD4 + T-cell restoration during antiretroviral therapy (ART) (ie, those with immune failure [IF] ) are at greater risk of developing these non-AIDS conditions [2] [3] [4] [5] [6] [0.6%-2.5%]; P = .35). CD11b (Mac-1), a member of the β2-integrin family, is involved in monocyte adhesion and endothelial transmigration as well as in macrophage activation. Constitutively present at low levels on the cell surface, its expression is increased after proinflammatory stimulation with cytokines (interleukin 1, tumor necrosis factor, and interferon γ) and lipopolysaccharide [9] . 
